---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-25-000048"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2025-11-17T23:59:59+00:00"
generated_at: "2026-05-16T19:12:33.900426+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Akebia amends Medice license to supply vadadustat and grant manufacturing rights

## Summary
- Amendment #1 to License Agreement signed Nov 12, 2025 with MEDICE Arzneimittel Putter GmbH & Co. KG.
- Akebia agrees to supply vadadustat drug substance under a concurrent supply agreement.
- Medice granted right to manufacture Vafseo tablets using supplied drug substance.
- Any know-how or patent rights from Medice's manufacturing owned by Akebia.

## SEC filing metadata
- accession: 0001517022-25-000048
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2025-11-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702225000048/0001517022-25-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702225000048/akba-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-25-000048
- JSON: https://secwatch.observer/filing/0001517022-25-000048.json
- Plain text: https://secwatch.observer/filing/0001517022-25-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.